InvestorsHub Logo
Followers 0
Posts 4
Boards Moderated 0
Alias Born 04/03/2023

Re: kenyonn2000 post# 222

Monday, 04/10/2023 2:20:01 AM

Monday, April 10, 2023 2:20:01 AM

Post# of 257
First line will be different and more derisked than R/R.
R/R : goal is an approval of 818 as MONOTHERAPY by achieve orr 25-30% and mDor > 6 MO
1s line : goal will be approval of 818 as a COMBINATION with CHOEP. Regarding the different kind of moa between these two treatments, we could anticipate in derisked manner and with confidence that if 818 will be approved in R/R as monotherapy, drug will be approved in 1st line to.
This is why I think it is a 2023 story.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRVS News